Venous thromboembolism: Current management

Abstract

Anticoagulation is indicated in most cases of venous thromboembolism. Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism. There are no recommended dose reductions for rivaroxaban or apixaban in venous thromboembolism, unlike for atrial fibrillation. The initial duration of anticoagulation is usually three months. Extended treatment with low-dose rivaroxaban or apixaban is effective in preventing recurrence in patients with a continuing increased risk of thromboembolism. Both drugs have low rates of major bleeding.